Revisione ed aggiornamento delle linee guida sulla ... - Anmco

R Mariotti, F Mauri - Linee guida dell’infarto miocardico acuto28. Maroko PR, Radvany P, Braunwald E, Hale SL. Reductionof infarct size by oxygen inhalation following acute coronaryocclusion. Circulation 1993; 87: 1542-50.29. Fillmore SJ, Shapiro M, Killip T. Arterial oxygen tension inacute myocardial infarction: serial analysis of clinical stateand blood gas changes. Am Heart J 1970; 79: 620-9.30. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardialinfarction: collaborative overview of early mortalityand major morbidity results from all randomised trials ofmore than 1000 patients. Lancet 1994; 343: 311-22.31. Gruppo Italiano per lo Studio della Sopravvivenza nell’InfartoMiocardico. GISSI-2. A factorial randomised trial ofalteplase vs streptokinase and heparin versus non heparinamong 12 490 patients with acute myocardial infarction.Lancet 1990; 336: 65-71.32. The International Study Group. In-hospital mortality andclinical course of 20 891 patients with suspected acute myocardialinfarction randomised between alteplase and streptokinasewith or without heparin. Lancet 1990; 336: 71-5.33. ISIS-3 (Third International Study of Infarct Survival) CollaborativeGroup. ISIS-3. A randomised comparison ofstreptokinase vs tissue plasminogen activator vs anistreplaseand of aspirin plus heparin vs aspirin alone among41 299 cases of suspected acute myocardial infarction.Lancet 1992; 339: 753-70.34. The GUSTO Investigators. An international randomized trialof comparison between four thrombolytic strategies foracute myocardial infarction. N Engl J Med 1993; 329: 673-82.35. GUSTO Angiographic Investigators. The effects of tissueplasminogen activator, streptokinase, or both on coronaryarterypatency, ventricular function, and survival after acutemyocardial infarction. N Engl J Med 1993; 22: 1615-22.36. van de Werf F. Streptokinase … never again. (editorial) EurHeart J 1999; 20: 1215.37. The Global Use of Strategies to Open Coronary Arteries(GUSTO III) Investigators. A comparison of reteplase withalteplase for acute myocardial infarction. N Engl J Med1997; 337: 1118-23.38. Assessment of the Safety and Efficacy of New Thrombolytic(ASSENT-2) Investigators. Single-bolus tenecteplasecompared with front-loaded alteplase in acute myocardialinfarction: the ASSENT-2 double-blind randomised trial.Lancet 1999; 354: 716-22.39. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patientswith acute myocardial infarction who are ineligiblefor thrombolytic therapy. Ann Intern Med 1991; 115: 173-7.40. The Global Use of Strategies to Open Occluded CoronaryArteries in Acute Coronary Syndromes (GUSTO IIb) AngioplastySubstudy Investigators. A clinical trial comparingprimary coronary angioplasty with tissue plasminogen activatorfor acute myocardial infarction. N Engl J Med 1997;336: 1621-8.41. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship betweendelay in performing direct coronary angioplasty andearly clinical outcome in patients with acute myocardial infarction:results from the Global Use of Strategies to OpenOccluded Arteries in Acute Coronary Syndromes (GUSTOIIb) trial. Circulation 1999; 100: 14-20.42. Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCKInvestigators. Early revascularization in acute myocardialinfarction complicated by cardiogenic shock. N Engl J Med1999; 341: 625-34.43. Antoniucci D, Santoro GM, Bolognese L, et al. A clinicaltrial comparing primary stenting of the infarct-related arterywith optimal primary angioplasty for acute myocardial infarction:results from the FRESCO trial. J Am Coll Cardiol1998; 31: 1234-9.44. Suryapranata H, vant’t Hoh AWJ, Hoorntje JCA, et al. Randomizedcomparison of coronary stenting with balloon angioplastyin selected patients with acute myocardial infarction.Circulation 1998; 97: 2502-5.45. The FRAX.I.S. Study Group. Comparison of two treatmentdurations (6 days and 14 days) of low molecular weight heparinwith a 6-day treatment of unfractionated heparin in theinitial management of unstable angina or non-Q wave myocardialinfarction: FRAX.I.S (FRAxiparine in IschaemicSyndrome). Eur J Cardiol 1999; 20: 1553-62.46. Fragmin and Fast Revascularisation during Instability inCoronary Artery Disease (FRISC II) Investigators. Longtermlow-molecular-mass heparin in unstable coronaryarterydisease: FRISC II prospective randomised multicentrestudy. Lancet 1999; 354: 701-7.47. Antman EM, Cohen M, Radley D, et al. Assessment of thetreatment effect of enoxaparin for unstable angina/non-Qwavemyocardial infarction TIMI 11B-ESSENCE metaanalysis.Circulation 1999; 100: 1602-8.48. Roux S, Christeller S, Ludin E. Effects of aspirin on coronaryocclusion and recurrent ischemia after thrombolysis: ameta-analysis. J Am Coll Cardiol 1992; 19: 671-7.49. Antiplatelet Trialists’ Collaboration. Collaborative overviewof randomised trials of antiplatelet therapy-I: Preventionof death, myocardial infarction, and stroke by prolongedantiplatelet therapy in various categories of patients.BMJ 1994; 308: 81-106.50. Roberts R, Rogers WJ, Mueller HS, et al, for the TIMI Investigators.Immediate versus deferred beta blockade followingthrombolytic therapy in patients with acute myocardialinfarction: results of the Thrombolysis in MyocardialInfarction (TIMI) IIB Study. Circulation 1991; 83: 422-37.51. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockadeduring and after myocardial infarction. An overview ofthe randomized trials. Prog Cardiovasc Dis 1985; 17: 335-71.52. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenousnitrates on mortality in acute myocardial infarction:an overview of randomised trials. Lancet 1988; 1: 1088-92.53. The European Study on Prevention of Infarction with Molsidomine(ESPRIM) Group. The ESPRIM trial: short-termtreatment of acute myocardial infarction with molsidomine.Lancet 1994; 344: 91-7.54. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L,Wedel H, on behalf of the CONSENSUS II Study Group.Effects of early administration of enalapril on mortality inpatients with acute myocardial infarction: results of the CooperativeNew Scandinavian Enalapril Survival Study II(CONSENSUS II). N Engl J Med 1992; 327: 678-84.55. Coats AJS. ACE inhibitors after myocardial infarction: selectionand treatment for all. Br Heart J 1995; 73: 395-6.56. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, forthe Meeting Participants. ACE inhibitor use in patients withmyocardial infarction. Summary of evidence from clinicaltrials. Circulation 1995; 92: 3132-7.57. Gibson RS, Boden WE, Theroux P, et al, and the DiltiazemReinfarction Study Group. Diltiazem and reinfarction in patientswith non-Q-wave myocardial infarction. N Engl JMed 1986; 315: 423-9.58. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonistsin myocardial infarction or angina in light of theSecond Danish Verapamil Infarction Trial (DAVIT-II) andother recent studies. Am J Cardiol 1991; 67: 1295-7.59. Peel AAF, Semple T, Wang I, Lancaster WM, Dall JLG. Acoronary prognostic index for grading the severity of infarction.Br Heart J 1962; 24: 745-60.549